The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

201–225 of 470

  • SevereFDA (Drugs)·D-753-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levalbuterol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levalbuterol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levalbuterol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-513-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aminocaproic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Aminocaproic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Aminocaproic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-907-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfathiazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfathiazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.

    Product
    Sulfathiazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-557-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcium Sulfate Hemihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Calcium Sulfate Hemihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Calcium Sulfate Hemihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-754-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levetiracetam Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levetiracetam active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levetiracetam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-653-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol (Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Estradiol (Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-787-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methscopolamine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-600-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cortisone Acetate Micronized Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cortisone Acetate Micronized active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cortisone Acetate Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-588-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ciprofloxacin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ciprofloxacin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Ciprofloxacin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-903-2015·2015-04-29

    Attix Pharmaceuticals Recalls Spectinomycin Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Spectinomycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Spectinomycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-954-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vincristine Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vincristine Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Vincristine Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-765-2015·2015-04-29

    Attix Pharmaceuticals Recalls Liothyronine Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Liothyronine Sodium (T3) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Liothyronine Sodium (T3) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-709-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Ophthalmic Grade) because it was repackaged in a facility with penicillin products, posing a cross-contamination risk.

    Product
    Hyaluronic Acid Sodium Salt (Ophthalmic Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-556-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcitriol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling calcitriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Calcitriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-813-2015·2015-04-29

    Attix Pharmaceuticals Recalls Naproxen Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Naproxen Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Naproxen Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-500-2015·2015-04-29

    Attix Pharmaceuticals Recalls Acetylsalicyclic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling acetylsalicyclic acid active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Acetylsalicyclic acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-770-2015·2015-04-29

    Losartan Potassium Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Losartan Potassium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Losartan Potassium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-773-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mechlorethamine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mechlorethamine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mechlorethamine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-661-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ethinyl Estradiol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Ethinyl Estradiol active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Ethinyl Estradiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-762-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lidocaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Lidocaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Lidocaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-563-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carboxymethyl Cellulose Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carboxymethyl Cellulose Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Carboxymethyl Cellulose Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-890-2015·2015-04-29

    Attix Pharmaceuticals Recalls Seratonin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Seratonin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed nationwide to compounding pharmacies and research organizations.

    Product
    Seratonin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-491-2015·2015-04-29

    Attix Pharmaceuticals Recalls 5-Aminolevulinic Acid Hydrochloride Due to Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling 5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-627-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexrazoxane Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Dexrazoxane active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dexrazoxane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-824-2015·2015-04-29

    Attix Pharmaceuticals Recalls Omeprazole Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Omeprazole Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Omeprazole Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide